Estimates Revisions Madrigal Pharmaceuticals, Inc. NYSE
Stocks
US5588681057
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
| 07-22 | BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $553 From $542 | MT |
| 07-21 | Madrigal Pharmaceuticals Insider Sold Shares Worth $1,368,253, According to a Recent SEC Filing | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- MDGL Stock
- Stock
- Consensus Madrigal Pharmaceuticals, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
